Allopurinol and Pathogenesis of Cirrhosis

Allopurinol Interferes With the Pathological Mechanisms of Hepatic Decompensation

NCT07033533•Tanta University

View on ClinicalTrials.gov

Summary

Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age 18-75 both sex

Exclusion Criteria

•active GIT bleeding

Locations (1)

Tanta University

Tanta, Egypt

Key Dates

Start Date

June 1, 2023

Primary Completion Date

March 1, 2024

Completion Date

March 1, 2024

Last Updated

June 24, 2025

Enrollment

100

ACTUAL participants

Conditions

Cirrhoses, Liver

Interventions

Allopurinol Tablet

DRUG

Placebo

DRUG

Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial

NCT07267260

Cirrhoses, Liver

View study

RECRUITINGNA

Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients

NCT07205471

Cirrhoses, LiverSplenectomy; Status+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions